Cargando...
Ranolazine Attenuates Behavioral Signs of Neuropathic Pain
Ranolazine modulates the cardiac voltage-gated sodium channel (Na(v) 1.5) and is FDA-approved for the treatment of ischemic heart disease. Ranolazine also targets neuronal (Na(v) 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine...
Gardado en:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2009
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2975014/ https://ncbi.nlm.nih.gov/pubmed/19773645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FBP.0b013e3283323c90 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|